AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Reviva Pharmaceuticals Holdings, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00LJZ8FX7
0.45▼ 0.03 (-5.68%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.48
Day's Range
0.41 – 0.50
52-Week Range
0.17 – 3.52
Volume
13.0K
Avg Volume
26.0K
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2020-12-15
Share count as of August 13, 2026

Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)
What is Reviva Pharmaceuticals Holdings, Inc. Common Stock's Market Cap?
Reviva Pharmaceuticals Holdings, Inc. Common Stock's Market Cap is $5.9M, based on as-reported figures from SEC (XBRL) filings.
What is Reviva Pharmaceuticals Holdings, Inc. Common Stock's Enterprise Value?
Reviva Pharmaceuticals Holdings, Inc. Common Stock's Enterprise Value is -$13.9M, based on as-reported figures from SEC (XBRL) filings.
What is Reviva Pharmaceuticals Holdings, Inc. Common Stock's Net Income (TTM)?
Reviva Pharmaceuticals Holdings, Inc. Common Stock's Net Income (TTM) is -$13.0M, based on as-reported figures from SEC (XBRL) filings.
What is Reviva Pharmaceuticals Holdings, Inc. Common Stock's Diluted EPS (TTM)?
Reviva Pharmaceuticals Holdings, Inc. Common Stock's Diluted EPS (TTM) is -0.99, based on as-reported figures from SEC (XBRL) filings.
What is Reviva Pharmaceuticals Holdings, Inc. Common Stock's Net Debt?
Reviva Pharmaceuticals Holdings, Inc. Common Stock's Net Debt is -$19.7M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RVPHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Gain on remeasurement of warrant liabilities
Interest expense
Interest income
Other expense, net
Total other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
Basic and diluted (in dollars per share)—